Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21994932 | 1.00 | KDM1A (0.43) | KDM1AHTR2ASIGMAR1PLAUIDO1 | |
| SCHEMBL22788416 | 0.98 | KDM1A (0.42) | KDM1AHTR2ASIGMAR1PLAUIDO1 | |
| SCHEMBL21995053 | 0.98 | KDM1A (0.42) | KDM1AHTR2ASIGMAR1PLAUIDO1 | |
| SCHEMBL21995278 | 0.98 | KDM1A (0.42) | KDM1AHTR2ASIGMAR1PLAUIDO1 | |
| SCHEMBL22442430 | 0.98 | KDM1A (0.42) | KDM1AHTR2ASIGMAR1PLAUIDO1 | |
| SCHEMBL21995277 | 0.98 | KDM1A (0.42) | KDM1AHTR2ASIGMAR1PLAUIDO1 | |
| SCHEMBL21995054 | 0.98 | KDM1A (0.42) | KDM1AHTR2ASIGMAR1PLAUIDO1 | |
| SCHEMBL22456838 | 0.98 | KDM1A (0.42) | KDM1AHTR2ASIGMAR1PLAUIDO1 | |
| SCHEMBL22456949 | 0.98 | KDM1A (0.42) | KDM1AHTR2ASIGMAR1PLAUIDO1 | |
| SCHEMBL29527555 | 0.98 | KDM1A (0.42) | KDM1AHTR2ASIGMAR1PLAUIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-11492361-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-08 | — | — | US | disclosed |
| US-20220119417-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3886987-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-10-06 | — | — | EP | disclosed |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-14 | — | — | US | disclosed |
| US-10870663-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| WO-2020110056-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119417-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | KDM1A 4469/4885HTR2A 4620/4885SIGMAR1 2713/4885 |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | KDM1A 4469/4885HTR2A 4620/4885SIGMAR1 2713/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | KDM1A 4469/4885HTR2A 4620/4885SIGMAR1 2713/4885 |
| US-10870663-B2 | Compounds useful in HIV therapy | CCR5, SLC11A2, CD4 | KDM1A 3918/4885HTR2A 4594/4885SIGMAR1 2770/4885 |
| US-11492361-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | KDM1A 4358/4885HTR2A 4620/4885SIGMAR1 2227/4885 |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | CCR5, SLC11A2, CD4 | KDM1A 3918/4885HTR2A 4594/4885SIGMAR1 2770/4885 |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | KDM1A 4358/4885HTR2A 4620/4885SIGMAR1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.